RTP Mobile Logo

BCU115

OVERVIEW OF ACTIVITY
Breast cancer (BC) continues to be one of the most rapidly evolving fields in medical oncology. Results from numerous ongoing trials lead to the continual emergence of new therapeutic agents, treatment strategies and diagnostic and prognostic tools. In order to offer optimal patient care — including the option of clinical trial participation — the practicing cancer clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME activity is designed to assist medical oncologists, hematologist-oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

IASLCMutations15

TARGET AUDIENCE
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).

IASLCNSCLC15

TARGET AUDIENCE
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).

LeukemiaTT115/Audio

OVERVIEW OF ACTIVITY

IASLCImmunotherapy15

TARGET AUDIENCE
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).

Lung Cancer Update, Issue 1, 2015

OVERVIEW OF ACTIVITY

GrandRoundsCLL15

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologists and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

COCMM15/3

OVERVIEW OF ACTIVITY

LCUTT115/Audio

OVERVIEW OF ACTIVITY

iJournal Club - Lung Cancer: 2015

OVERVIEW OF ACTIVITY
Lung cancer is a devastating disease with broad-reaching impact on public health, as it accounts for 14% of all new cancer cases in the United States and the most cancer-related deaths among both men and women. In 2015, it is estimated that 221,200 new cases will be diagnosed and 158,040 deaths will occur from the disease. In addition, only 16% of all patients with lung cancer are alive 5 years or more after diagnosis, despite currently available therapies.

GrandRoundsLung15

TARGET AUDIENCE
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of lung cancer.

ASCOLung15

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).

ASCOBreast15

TARGET AUDIENCE
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer (BC).

RTPODBreast215

TARGET AUDIENCE
This activity is intended for medical and radiation oncologists, breast and general surgeons, hematology-oncology fellows and other healthcare providers involved in the treatment of breast cancer.

OVERVIEW OF ACTIVITY

RTPODBreast2015

TARGET AUDIENCE
This activity is intended for medical and radiation oncologists, breast and general surgeons, hematology-oncology fellows and other healthcare providers involved in the treatment of breast cancer.

OVERVIEW OF ACTIVITY